Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: new highs and I say bye cutting some positions

May 21, 2021 7:51am

A new pandemic-low in jobless claims helped sentiment but, will it assist sustainability?

Pre-open indications: 7 SELLs and 1 Maintain SELL

Mentions: AGTC, CRSP, EDIT, BLUE, KDNY, IONS, NTLA, BSTG

My version of the morning’s “indications” is written on what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!

Dow futures are UP +0.42% (+148 points), S&P futures are UP +0.38% (+16 points) and NASDAQ futures are UP +0.35% (+47 points)

Pre-open futures are higher Friday after indexes rebounded on Thursday from a three (3) day losing streak,

European markets were slightly higher

Asia-Pacific markets were mixed

Henry’omics:

We seem to be set-up for more gains as the week’s sessions end ...

Post Thursday’s rebound, the Dow is down 0.9% in the past week, on track to see its fourth (4^th) negative week out of the past five (5) weeks. The S&P 500 is 0.4% lower on the week, on pace for its second (2^nd) negative week in a row while the Nasdaq is up 0.8% and positioned to break a four (4) week losing streak.

But (the infamous pause), are we running into a wall of selling from a volatile week, maybe not today but (the second in a sentence) next week?

Data Docket: existing home sales for the month of April and IHS Markit’s will release its flash manufacturing and services reports for May.

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (30) to date … https://www.regmedinvestors.com/articles/11628

Thursday’s evening’s recap: “rebound” … https://www.regmedinvestors.com/articles/11920

The Nasdaq closed UP +236.00 points (+1.77%);
The IBB closed +2.03% and XBI closed up +2.10%;
Sector volume was LOW with 0 of the 28-upside having higher than the 3-month average volume with the volume of 1 of 5-downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was down -1.51 points or -6.81% at 20.67
Thursday’s percentage (%) of the 28-upside were +0.38% (AXGN) to +6.41% (CRSP) while the 5-downside ranges from -0.62% (NTLA) to -10.25% (VYGR);

Q2/21:

May: 5 positive and 9 negative closes

April: 11 negative and 10 positive closes

Q1/21:

March: 10 positive, 12 negative and 1 neutral closes
February: 9 positive, 10 negative closes and 1 holiday
January: 10 positive, 9 negative closes and 1 holiday

Companies in my headlights – It’s your decision; I provide an idea and context:

Biostage (BSTG): Questions continue … Maintaining Sell and still “pumping” the volume to keep price moving …

Biostage (BSTG) closed float at 41.30 with 1 share traded after Wednesday’s +$0.16 to $1.30 with 930 shares traded, Tuesday’s -$0.16 to $1.13 with 250 shares traded, Monday’s +$0.15 to $1.30 with 2,642 shares traded and last Friday’s flat with 54 shares traded.

Question#1: WHY is BSTG NOT filing the Q1 earnings’ report? Their interim financial officer, Peter A. Pellegrino Jr. of Point Providence Consulting has been appointed since 4/8/21 and still was NOT able to produce a Q1 report? Are there other issues – like being out of cash or soon to be?

Question#2: What is there to invest in, an IND a year old with NO clinical trial, NO management, barely any employees and huge overhead (buildings etc.) expense with WHAT capacity to finance? With only $1 million left (12/31/20) in the “till” WHAT is the runway with a “spend” and “net cash in operations of $4 million during the year ended 12/ 31/20”. Don’t forget the PPP loan remaining as DEBT ($0.4 million).

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

The morning’s indications:

Maintaining SELL:

Chinook Therapeutics (KDNY) closed up again +$0.62 to $17.49 after Wednesday’s +$0.68 to $16.87, Tuesday’s -$0.53 to $16.19 after Monday’s +$1.87 to $16.72 with NO aftermarket indication. If you sold as I have written, you would have made profits.

SELL from BUY:

Applied Genetic Technologies (AGTC) closed up +$0.20 to $4.30 after Wednesday’s $4.10, Tuesday’s $4.31, Monday’s $3.84 and last Friday’s $3.88 with a negative -$0.11 or -2.56% aftermarket indication.

bluebird bio (BLUE) closed up +$1.29 to $30.72 after Wednesday’s -$1.24 to $29.43, Tuesday’s +$0.76 to $30.67 and Monday’s -$0.41 to $29.91 with a negative -$0.15 or +0.49% pre-market indications.

Ionis Pharmaceuticals (IONS) closed up +$1.20 to $36.56 after Wednesday’s $35.36, Tuesday’s $36.87 after Monday’s +$37.32 with negative -$0.28 or -0.77% aftermarket indication. If you sold as I have written, you would have made profits.

Take some Profit off the Table, SELL into Highs or Strength:

Editas Medicine (EDIT) closed up =$1.07 to $34.18 after Wednesday’s -$0.46 to $33.11, Tuesday’s +$0.46 to $33.57 and Monday’s $33.11 with a positive +$0.07 or +0.20% pre-market indications.

Intellia Therapeutics (NTLA) closed down -$0.40 to $64.08 after Wednesday’s -$1.88 to $64.48, Tuesday’s $66.36 and Monday’s $66.69 with a positive +$0.23 or +0.36% pre-market indication.

CRISPR Therapeutics (CRSP) closed up +$7.09 to $117.65 after Wednesday’s -$2.10 to $110.56, Tuesday’s +$3.44 to $112.66 after Monday’s $109.22 and Friday’s $106.64 with a positive +$1.35 or +1.15% pre-market indication

The BOTTOM LINE: I foresee a pattern of increased volatility as we have been experiencing through these summer months.

I feel like a song from a broken record, “post earnings’ release, BUY some (few) short-term dips but, cautiously”.

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see some lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.